Psychiatry Service, Veterans Affairs Medical Center, 1970 Roanoke Boulevard (116A7), Salem, VA, 24153, USA,
Psychiatr Q. 2013 Dec;84(4):523-41. doi: 10.1007/s11126-013-9264-4.
A retrospective analysis was followed on 20 case reports covering the possible correlation between the atypical antipsychotic, quetiapine, and neuroleptic malignant syndrome (NMS), determined by the study of 7 different NMS criteria guidelines. A great majority (19) of the case studies did not meet the requirements of all 7 guidelines, frequently due to unreported information. Nor was quetiapine proven to be the sole cause of the possible NMS in the two age groups investigated. Only one case was found to have no other medication or medical conditions confounding the relationship of quetiapine and NMS symptoms, and that case was in the context of a significant quetiapine overdose. The other 19 cases demonstrated the difficulty of identifying the cause of NMS when polypharmacy and other medical conditions are involved. The authors note the need for caution in deciding both the presence of NMS and the causal factors of the symptoms.
对 20 例病例报告进行了回顾性分析,这些报告涵盖了非典型抗精神病药喹硫平与神经阻滞剂恶性综合征(NMS)之间可能存在的相关性,研究了 7 种不同的 NMS 标准指南。大多数(19 例)病例研究未满足所有 7 条指南的要求,这通常是由于未报告信息所致。也没有证据表明喹硫平是两个研究年龄段可能发生的 NMS 的唯一原因。只有 1 例病例未发现其他药物或医疗条件会影响喹硫平与 NMS 症状之间的关系,而且该病例的情况是喹硫平严重过量。其他 19 例病例表明,当涉及多种药物治疗和其他医疗条件时,确定 NMS 的原因具有一定难度。作者指出,在确定 NMS 的存在以及症状的因果因素时,需要谨慎。